Get it on Google Play

Bradley Pharmaceuticals (BDY) Received FDA Approval to market Polyphenon E Ointment

October 31, 2006 4:33 PM EST
Bradley Pharmaceuticals, Inc. (NYSE: BDY) has been notified by MediGene AG (Frankfurt, Prime Standard: MDG) that MediGene received FDA approval from the U.S. Food and Drug Administration (FDA) to market Polyphenon EŽ Ointment, 15%, a new drug indicated for the treatment of external genital and perianal warts and patented through 2017.

The product, developed by MediGene AG, will be commercialized in the United States by Bradley and is expected to launch during the second half of 2007. With FDA approval, MediGene is due a $14M milestone payment from Bradley.

You May Also Be Interested In

Related Categories